Devimistat (CPI-613®) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancer's T-Cell Lymphoma "Dream Team Research Grant"
Stock Information for Rafael Holdings Inc. Class B
Loading
Please wait while we load your information from QuoteMedia.